Sethuraman Gomathy, Yenamandra Vamsi K, Gupta Vishal
Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India.
J Cutan Aesthet Surg. 2014 Apr;7(2):75-85. doi: 10.4103/0974-2077.138324.
Infantile hemangiomas (IH) are common vascular tumours. IH have a characteristic natural course. They proliferate rapidly during the early infantile period followed by a period of gradual regression over several years. Most of the uncomplicated IH undergo spontaneous involution, with a small proportion of cases requiring intervention. These are children with IH in life-threatening locations, local complications like haemorrhage, ulceration and necrosis and functional or cosmetic disfigurements. Systemic corticosteroids have been the first line of treatment for many years. Recently, non-selective beta-blockers, such as oral propranalol and topical timolol, have emerged as promising and safer therapies. Other treatment options include interferon α and vincristine which are reserved for life-threatening haemangiomas that are unresponsive to conventional therapy. This review mainly focuses on the current trends and evidence-based approach in the management of IH.
婴儿血管瘤(IH)是常见的血管肿瘤。婴儿血管瘤具有独特的自然病程。它们在婴儿早期迅速增殖,随后在数年中逐渐消退。大多数无并发症的婴儿血管瘤会自发消退,只有一小部分病例需要干预。这些病例包括血管瘤位于危及生命部位的儿童、出现出血、溃疡和坏死等局部并发症以及功能或美容缺陷的儿童。多年来,全身用皮质类固醇一直是一线治疗方法。最近,非选择性β受体阻滞剂,如口服普萘洛尔和局部用噻吗洛尔,已成为有前景且更安全的治疗方法。其他治疗选择包括干扰素α和长春新碱,它们用于对传统治疗无反应的危及生命的血管瘤。本综述主要关注婴儿血管瘤治疗的当前趋势和循证方法。